| Treatment of polycystic ovary syndrome (PCOS) with metformin ameliorates insulin resistance in parallel with the decrease of serum interleukin-6 concentrations. | |
| | |
MedLine Citation:
|
PMID: 20730705 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Low-grade chronic inflammation underlies the pathogenesis of insulin-resistant disorders such as polycystic ovary syndrome (PCOS). We aimed to study if the changes observed in the insulin sensitivity of PCOS patients during treatment with oral contraceptives or metformin associate changes in the serum inflammatory markers interleukin-6 (IL-6) and interleukin-18 (IL-18). In a randomized open-label clinical trial (NLM Identifier NCT00428311), 34 PCOS patients were allocated to receive oral treatment with metformin (850 mg twice daily) or with the Diane (35) Diario contraceptive pill (35 μg of ethynylestradiol plus 2 mg of cyproterone acetate) for 24 weeks. Changes in serum IL-6 and IL-18 levels and insulin sensitivity index were monitored throughout the study. Eighteen women without hyperandrogenism served as controls for serum interleukin concentrations. PCOS women treated with metformin showed a decrease in IL-6 levels throughout the study compared with women treated with Diane (35) Diario (-33% change vs. +23% change, F=3.709, p=0.048; intention-to-treat analysis: F=5.569, p=0.011). There were no statistically significant changes in IL-18 concentrations with any treatment. The decrease in IL-6 levels in women receiving metformin occurred in parallel to the increase in the insulin sensitivity index (r=-0.579, p=0.048; intention-to-treat analysis, r=-0.687, p=0.001). In conclusion, serum IL-6 levels decreased during treatment with metformin in parallel to amelioration of insulin resistance, whereas oral contraceptives slightly increased circulating IL-6 levels without changing insulin sensitivity. Both drugs had a neutral effect on serum IL-18 concentrations. |
| | |
Authors:
|
M Luque-Ramírez; H F Escobar-Morreale |
Related Documents
:
|
8548945 - Androgens and insulin resistance in type 1 diabetic men. 3392175 - Ovulation prediction and detection with the cue ovulation predictor. 15644405 - Luteinizing hormone secretion is not influenced by insulin infusion in women with polyc... 15797965 - Changes in glucose tolerance over time in women with polycystic ovary syndrome: a contr... 18647955 - Inducible overexpression of sflt-1 in podocytes ameliorates glomerulopathy in diabetic ... 415735 - A species difference in nucleoside phosphorylase activity and inosine-stimulated insuli... |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial Date: 2010-08-20 |
Journal Detail:
|
Title: Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme Volume: 42 ISSN: 1439-4286 ISO Abbreviation: Horm. Metab. Res. Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-10-04 Completed Date: 2011-02-14 Revised Date: 2011-03-28 |
Medline Journal Info:
|
Nlm Unique ID: 0177722 Medline TA: Horm Metab Res Country: Germany |
Other Details:
|
Languages: eng Pagination: 815-20 Citation Subset: IM |
Copyright Information:
|
© Georg Thieme Verlag KG Stuttgart · New York. |
Affiliation:
|
Department of Endocrinology, Hospital Universitario Ramón y Cajal & Universidad de Alcalá & Instituto Ramón y Cajal de Investigación Sanitaria IRYCIS, Madrid, Spain. |
| Data Bank Information | |
Bank Name/Acc. No.:
|
ClinicalTrials.gov/NCT00428311 |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Female Humans Hypoglycemic Agents / therapeutic use* Insulin Resistance* Interleukin-18 / blood Interleukin-6 / blood* Metformin / therapeutic use* Polycystic Ovary Syndrome / blood*, drug therapy* |
| Chemical | |
Reg. No./Substance:
|
0/Hypoglycemic Agents; 0/Interleukin-18; 0/Interleukin-6; 657-24-9/Metformin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The effect of maternal hypothyroidism on the carbohydrate metabolism and insulin secretion of isolat...
Next Document: Sorafenib.